Endocrine Disorders in Childhood Brain Tumour Survivors: A Single-Centre Study

Overview

Journal J ASEAN Fed Endocr Soc

Specialty Endocrinology

Date 2024 Jun 12

PMID 38863912

Authors

Nurul Wahidah Ramezan

Suhaimi Hussain

Norsarwany Mohamad

Najib Majdi Yaacob

Affiliations

Soon will be listed here.

Abstract

Objective: The study aims to determine the prevalence and risk factors for endocrine disorders in childhood brain tumour survivors.

Methodology: Included in the study were 124 childhood brain tumour survivors aged 18 years old or younger with either stable disease or in remission, and had survived for at least 2 years after diagnosis. Demographic data (age at diagnosis, gender, ethnicity, socioeconomic status), clinical clues for endocrine disorders, anthropometrics (weight, height, midparental height), pubertal staging, tumour-related characteristics, treatment modalities and endocrine laboratory measurements at diagnosis and during follow up were obtained. Logistic regression was applied to evaluate risk factors for endocrine disorders in childhood brain tumour survivors.

Results: The prevalence of endocrine disorders in childhood brain tumour survivors was 62.1%. The risk factors were high BMI [adjusted odds ratio (OR) 1.29, 95% CI: 1.12 to 1.5], high-risk site [adjusted odds ratio (OR) 7.15, 95% CI: 1.41 to 36.3] and chemotherapy [adjusted odds ratio (OR) 0.18, 95% CI: 0.05 to 0.62].

Conclusion: The prevalence of endocrine disorders in childhood brain tumour survivors in our centre was 62.1%. The significant risk factors were high BMI, tumour location (suprasellar and intrasellar) and chemotherapy.

References

Yalcin B, Kremer L, van Dalen E . High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015; (10):CD006301. PMC: 8783746. DOI: 10.1002/14651858.CD006301.pub4. View

Kumar M, Foster J, Sharan S, DeRibaupierre S, McKillop S, Kornecki A . Transient blindness as the primary symptom of acute hyponatremia post surgery. J Pediatr Intensive Care. 2019; 1(3):169-172. PMC: 6530693. DOI: 10.3233/PIC-2012-028. View

Shaw S . Endocrine late effects in survivors of pediatric brain tumors. J Pediatr Oncol Nurs. 2009; 26(5):295-302. DOI: 10.1177/1043454209343180. View

Clement S, Schouten-van Meeteren A, Kremer L, van Trotsenburg A, Caron H, van Santen H . High prevalence of early hypothalamic-pituitary damage in childhood brain tumor survivors: need for standardized follow-up programs. Pediatr Blood Cancer. 2014; 61(12):2285-9. DOI: 10.1002/pbc.25176. View

Chemaitilly W, Li Z, Huang S, Ness K, Clark K, Green D . Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015; 33(5):492-500. PMC: 4314596. DOI: 10.1200/JCO.2014.56.7933. View

Oberfield S, Allen J, Pollack J, New M, LEVINE L . Long-term endocrine sequelae after treatment of medulloblastoma: prospective study of growth and thyroid function. J Pediatr. 1986; 108(2):219-23. DOI: 10.1016/s0022-3476(86)80986-6. View

Khanal N, Ahmed S, Kalra M, Miller T, Brames M, Stump T . The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy. Support Care Cancer. 2019; 28(7):3165-3170. DOI: 10.1007/s00520-019-05117-0. View

Chemaitilly W, Cohen L, Mostoufi-Moab S, Patterson B, Simmons J, Meacham L . Endocrine Late Effects in Childhood Cancer Survivors. J Clin Oncol. 2018; 36(21):2153-2159. DOI: 10.1200/JCO.2017.76.3268. View

Ostrom Q, de Blank P, Kruchko C, Petersen C, Liao P, Finlay J . Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 10:x1-x36. PMC: 4277295. DOI: 10.1093/neuonc/nou327. View

10.

Ng Y, Jalaludin M, Foo J, Qaddoumi I, Rajagopal R . Prevalence and Risk Factors for Endocrine Disorders in Childhood Brain Tumors From a Single Tertiary Center in Malaysia. J Pediatr Hematol Oncol. 2022; 44(4):159-166. DOI: 10.1097/MPH.0000000000002447. View

11.

Patterson B, Wasilewski-Masker K, Ryerson A, Mertens A, Meacham L . Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab. 2011; 97(3):810-8. DOI: 10.1210/jc.2011-2104. View

12.

Fang F, Rosenblum J, Ho W, Heiss J . New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. Cancers (Basel). 2022; 14(9). PMC: 9100249. DOI: 10.3390/cancers14092285. View

13.

Maciel J, Dias D, Cavaco D, Donato S, Pereira M, Simoes-Pereira J . Growth hormone deficiency and other endocrinopathies after childhood brain tumors: results from a close follow-up in a cohort of 242 patients. J Endocrinol Invest. 2021; 44(11):2367-2374. DOI: 10.1007/s40618-021-01541-4. View

14.

Cooksey R, Wu S, Klesse L, Oden J, Bland R, Hodges J . Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors. J Investig Med. 2018; 67(2):295-302. DOI: 10.1136/jim-2018-000911. View

15.

Lawson S, Horne V, Golekoh M, Hornung L, Burns K, Fouladi M . Hypothalamic-pituitary function following childhood brain tumors: Analysis of prospective annual endocrine screening. Pediatr Blood Cancer. 2019; 66(5):e27631. DOI: 10.1002/pbc.27631. View

16.

Clement S, Schouten-van Meeteren A, Boot A, Claahsen-van der Grinten H, Granzen B, Sen Han K . Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. J Clin Oncol. 2016; 34(36):4362-4370. DOI: 10.1200/JCO.2016.67.5025. View

17.

Lustig R, Post S, Srivannaboon K, Rose S, Danish R, Burghen G . Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003; 88(2):611-6. DOI: 10.1210/jc.2002-021180. View

18.

Pasqualini T, Diez B, Domene H, Escobar M, Gruneiro L, Heinrich J . Long-term endocrine sequelae after surgery, radiotherapy, and chemotherapy in children with medulloblastoma. Cancer. 1987; 59(4):801-6. DOI: 10.1002/1097-0142(19870215)59:4<801::aid-cncr2820590424>3.0.co;2-z. View

19.

Zaid M, Dinh P, Monahan P, Fung C, El-Charif O, Feldman D . Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. J Natl Compr Canc Netw. 2019; 17(5):459-468. PMC: 6712564. DOI: 10.6004/jnccn.2018.7109. View

20.

Das U . Obesity: genes, brain, gut, and environment. Nutrition. 2009; 26(5):459-73. DOI: 10.1016/j.nut.2009.09.020. View